SEQUENCE LISTING

<110> VEDANTRA PHARMACEUTICALS, INC.

<120> CPG AMPHIPHILES AND USES THEREOF

<130> 51026-027WO2

<140> PCT/US19/20398
<141> 2019-03-01

<150> US 62/637,824
<151> 2018-03-02

<160> 14

<170> PatentIn version 3.5

<210> 1
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 1
tcgtcgtttt gtcgttttgt cgtt 24

<210> 2
<211> 158
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 2

Met His Gln Lys Arg Thr Ala Met Phe Gln Asp Pro Gln Glu Arg Pro
1 5 10 15

Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile His Asp
20 25 30

Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu
35 40 45

```
Val Tyr Asp Phe Ala Phe Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly
    50                  55                  60

Asn Pro Tyr Ala Val Gly Asp Lys Cys Leu Lys Phe Tyr Ser Lys Ile
65                  70                  75                  80

Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu
                85                  90                  95

Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile Asn
            100                 105                 110

Gly Gln Lys Pro Leu Cys Pro Glu Glu Lys Gln Arg His Leu Asp Lys
        115                 120                 125

Lys Gln Arg Phe His Asn Gly Arg Gly Arg Trp Thr Gly Arg Cys Met
    130                 135                 140

Ser Cys Cys Arg Ser Ser Arg Thr Arg Arg Glu Thr Gln Leu
145                 150                 155
```

<210> 3
<211> 98
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 3

```
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1               5                   10                  15

Pro Glu Thr Thr Asp Leu Tyr Gly Tyr Gly Gln Leu Asn Asp Ser Ser
            20                  25                  30

Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
        35                  40                  45
```

Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60

Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80

Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95

Lys Pro

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 4
tccatgacgt tcctgacgtt 20

<210> 5
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 5
ggtccatgac gttcctgacg tt 22

<210> 6
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 6
tcgtcgtttt gtcgttttgt cgtt 24

<210> 7
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 7

Arg Ala His Tyr Asn Ile Val Thr Phe
1 5

<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 8

Glu Val Tyr Asp Phe Ala Phe Arg Asp Leu
1 5 10

<210> 9
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 9

Val Tyr Asp Phe Ala Phe Arg Asp Leu
1 5

<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 10

Cys Val Tyr Cys Lys Gln Gln Leu Leu
1   5

<210> 11
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 11

Lys Cys Leu Lys Phe Tyr Ser Lys Ile
1   5

<210> 12
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 12

Asn Lys Pro Leu Cys Asp Leu Leu Ile
1   5

<210> 13
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 13

Arg Ala His Tyr Asn Ile Val Thr Phe
1   5

<210> 14
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 14

Ser Ile Ile Asn Phe Glu Lys Leu
1   5